PYRGF vs. CMPX, AVIR, TERN, ACB, SLDB, ATXS, SLRN, CDTX, HUMA, and DRUG
Should you be buying PyroGenesis Canada stock or one of its competitors? The main competitors of PyroGenesis Canada include Compass Therapeutics (CMPX), Atea Pharmaceuticals (AVIR), Terns Pharmaceuticals (TERN), Aurora Cannabis (ACB), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Acelyrin (SLRN), Cidara Therapeutics (CDTX), Humacyte (HUMA), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry.
PyroGenesis Canada vs.
PyroGenesis Canada (NASDAQ:PYRGF) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap industrials companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.
0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by insiders. Comparatively, 28.5% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Compass Therapeutics had 14 more articles in the media than PyroGenesis Canada. MarketBeat recorded 14 mentions for Compass Therapeutics and 0 mentions for PyroGenesis Canada. Compass Therapeutics' average media sentiment score of 0.52 beat PyroGenesis Canada's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media.
Compass Therapeutics received 46 more outperform votes than PyroGenesis Canada when rated by MarketBeat users.
Compass Therapeutics has a consensus price target of $13.38, indicating a potential upside of 589.43%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than PyroGenesis Canada.
PyroGenesis Canada has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.
PyroGenesis Canada has higher revenue and earnings than Compass Therapeutics. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.
Compass Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Compass Therapeutics' return on equity.
Summary
Compass Therapeutics beats PyroGenesis Canada on 13 of the 18 factors compared between the two stocks.
Get PyroGenesis Canada News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYRGF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PYRGF vs. The Competition
PyroGenesis Canada Competitors List
Related Companies and Tools
This page (NASDAQ:PYRGF) was last updated on 4/26/2025 by MarketBeat.com Staff
Buy PYRGF Stock Free PYRGF Stock Alerts